Charles River Divests Contract Development and Manufacturing Business

Feb 10 2017

Today, Charles River completed the divestiture of its CDMO business to Quotient Clinical. As a result, small-molecule manufacturing services are no longer available.

To learn more about the divestiture, click here.

You may also be interested in...

Safety Assessment

Our preclinical drug safety and efficacy testing is in compliance with global regulatory agency guidelines.

Clinical Support

Charles River supports clinical trials with in vivo and in vitro nonclinical studies and clinical-scale manufacturing.